Tech | run4unblocked.com

How to Scale Biomanufacturing Processes for Cell and Gene Therapy

For years, the cell and gene therapy (CGT) sector was defined by bespoke, small-batch, manual benchtop production. These labor-intensive methods were necessary to prove clinical efficacy in early-stage trials, but they are entirely unsustainable for commercial delivery.

Today, the industry faces a pressing modern mandate: industrialize and scale. As these advanced genetic medicines transition from experimental breakthroughs to standard-of-care treatments, the primary industry bottleneck has shifted from scientific discovery to reproducible, cost-effective manufacturing. Successfully scaling CGT biomanufacturing requires transitioning from open manual operations to standardized, automated, closed-system processing and robust vector optimization to ensure long-term commercial viability.

Overcoming Bottlenecks in Viral Vector Production

Viral vectors—such as adeno-associated viruses (AAV) and lentiviruses—are the critical delivery vehicles for genetic therapies, yet their production remains notoriously difficult to scale:

Scaling Plasmid and Viral Vector Yields: Traditional transient transfection protocols struggle with batch-to-batch variability and high reagent costs. The industry is rapidly shifting toward

Modern Technology

Cost of Implementing Custom Artificial Intelligence Solutions for Enterprise Businesses

August 18, 2026September 28, 2026 - by Reynaldi Rafiq

Many corporate leadership teams fall into the trap of viewing artificial intelligence through the lens of consumer subscription pricing. They contrast the illusion of “cheap” off-the-shelf APIs with the complex financial reality of building, training, and maintaining a custom enterprise-grade AI solution.

As organizations move beyond generic chatbots toward proprietary, domain-specific models, they realize that custom AI requires a major capital commitment. Accurately budgeting for custom enterprise AI requires looking far beyond initial development costs to encompass compute infrastructure, data engineering, ongoing maintenance, and long-term risk management.

Capital Expenditure (CapEx) vs. Operating Expenditure (OpEx)

Building a proprietary AI solution from the ground up demands a careful evaluation of initial financial outlays across hardware, data, and human capital:

Compute and Infrastructure Investments: Training or fine-tuning advanced models requires staggering amounts of computational power. Enterprises must budget for high-performance GPUs (such as NVIDIA H100s or next-generation accelerators), dedicated cloud clusters across AWS,

Modern Technology

Step-by-Step Guide to Build a Custom IoT Object with Raspberry Pi

August 6, 2026September 28, 2026 - by Reynaldi Rafiq

Off-the-shelf smart home gadgets are convenient, but they are often restricted by closed ecosystems, proprietary apps, and rigid feature sets. For developers and makers who want total control over their hardware, building a custom connected device is the ultimate solution.

The Raspberry Pi ecosystem empowers engineers to prototype industrial-grade smart objects quickly and affordably. By combining low-cost sensors, Python programming, and lightweight messaging protocols, you can transform a single-board computer into a fully functional, cloud-connected IoT monitoring node.

Hardware Bill of Materials and Architecture

Before writing a single line of code, you need to assemble the physical building blocks of your IoT node:

Core Processor: The Raspberry Pi Zero 2 W or Raspberry Pi 4/5 serves as the brain of the project, providing built-in Wi-Fi and Bluetooth connectivity for remote data transmission.

Sensors and Actuators: For this build, we will use a DHT22 temperature and humidity sensor, an RGB

Modern Technology

Ethical Considerations of Synthetic Biology in Medical Biotechnology

July 28, 2026September 28, 2026 - by Reynaldi Rafiq

For centuries, the practice of medicine was defined by discovery—finding naturally occurring molecules, medicinal plants, and biological compounds, and modifying them for human healing. Today, we stand in a radical new paradigm: synthetic biology.

Instead of merely modifying existing biology, scientists now write novel genetic code from scratch to construct custom cellular therapeutics, engineered immune cells, and synthetic gene circuits. While these tools open unprecedented frontiers in treating cancers, rare genetic disorders, and complex immune conditions, engineering living systems introduces profound ethical, safety, and governance challenges that demand rigorous moral scrutiny.

Core Ethical Dilemmas in Medical SynBio

Synthesizing life and programming cellular behavior creates unique moral hazards that differ fundamentally from traditional pharmaceuticals. Several core dilemmas define this emerging ethical landscape:

Biosafety and Unintended Ecological Release: Unlike small-molecule drugs that degrade over time, engineered biological constructs are self-replicating. The accidental escape, environmental persistence, or horizontal gene transfer of synthetic vectors

Modern Technology

Ethical Challenges of Artificial Intelligence in Corporate Business Decision Making

June 22, 2026September 28, 2026 - by Reynaldi Rafiq

For generations, corporate governance was defined by human deliberation—fraught with conscious biases, emotional blind spots, and cognitive fatigue. Today, modern boardrooms are rushing to embrace artificial intelligence, drawn to the promise of lightning-fast, seemingly objective, data-driven decision-making.

Artificial intelligence has rapidly evolved from an operational back-office tool into the highest levels of strategic planning, resource allocation, and talent management. However, while AI promises unprecedented analytical depth, automating corporate decisions introduces profound ethical dilemmas that challenge traditional accountability, transparency, and fiduciary responsibility.

The Core Ethical Fault Lines in Corporate AI

Integrating algorithms into corporate strategy creates unique moral hazards that differ fundamentally from traditional software deployment. Several core fault lines define this new ethical landscape:

Algorithmic Bias and Discrimination: AI models learn from historical data. If past corporate data reflects systemic biases, the algorithm internalizes and scales those prejudices—leading to discriminatory outcomes in automated hiring, credit scoring, and customer profiling.

The